Jeanine Herrera
Primary Care · Ozark, MONPI 1558774976
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $959, more than ten times the $83 reported in 2021.
Across 125 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$381
- Lilly USA, LLC$244
- Novo Nordisk$191
- Axsome Therapeutics, Inc.$186
- Pfizer$176
- GSK$133
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,390100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $381 |
| Lilly USA, LLC | 15 | $244 |
| Novo Nordisk | 10 | $191 |
| Axsome Therapeutics, Inc. | 4 | $186 |
| Pfizer | 14 | $176 |
| GSK | 3 | $133 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Alkermes, Inc. | 6 | $124 |
| Lundbeck LLC | 7 | $118 |
| Neurocrine Biosciences, Inc. | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Merck | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $67 |
| Exact Sciences | 3 | $47 |
| Johnson & Johnson | 2 | $46 |
| Astellas Pharma US Inc | 1 | $25 |
| Edwards Lifesciences | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
| Bayer | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$125
How this compares
$2,390 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $40,813 |
| JardianceEmpagliflozin | 27 | $30,530 |
| EliquisApixaban | 29 | $27,488 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $27,151 |
| LinzessLinaclotide | 40 | $25,442 |
| RexultiBrexpiprazole | 11 | $16,400 |
| MounjaroTirzepatide | 15 | $15,940 |
| Spiriva RespimatTiotropium Bromide | 24 | $14,754 |
| FarxigaDapagliflozin Propanediol | 11 | $14,258 |
| KerendiaFinerenone | 13 | $8,427 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,300 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,317 |
| NovologInsulin Aspart | 13 | $3,769 |
| Celecoxib | 157 | $3,569 |
| Aripiprazole | 50 | $3,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $191 | $44,58241 claims |
| PfizerEliquis | $176 | $27,48829 claims |
| AbbVieLinzess | $381 | $25,44240 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $244 | $16,63344 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $133 | $16,40011 claims |
| BayerKerendia | $14 | $8,42713 claims |
| GSKBreo Ellipta | $133 | $5,31713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Missouri.
Other primary care in Ozark
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Taylor HeathSparta$3K
- Ashley TitchenalSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.